Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis
Status:
Completed
Trial end date:
2017-12-12
Target enrollment:
Participant gender:
Summary
This clinical study will be a single-center, randomized, open-label, active-controlled,
parallel-group study comparing dalbavancin to standard of care (SOC) therapy in
osteomyelitis.
Phase:
Phase 2
Details
Lead Sponsor:
Durata Therapeutics Inc., an affiliate of Allergan plc